partnership
Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in an $85-per-share cash deal.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Wed · 15 Jul
partnership
Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in an $85-per-share cash deal.
Markets open original ↗
partnership
GSK completed its $10.6 billion acquisition of Nuvalent.
Markets open original ↗
partnership
Redwire shares climbed after the company secured a $21.5 million U.S. defense contract.
Markets open original ↗
product
Regeneron suffered a clinical trial setback, according to a report questioning whether the stock remains cheap.
Markets open original ↗
funding
Vulcan Energy drew the first tranche of its €2.2 billion Lionheart project funding.
Markets open original ↗